MEI Pharma

MEI Pharma, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical compounds. Its products include Zandelisib, Voruciclib, and ME-344. The company was founded on December 1, 2000 and is headquartered in San Diego, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MEI Pharma, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical compounds. Its programs include Voruciclib and ME-344. The company was founded on December 1, 2000, and is headquartered in San Diego, CA.

Infinity Pharma

MEI Pharma and Infinity Pharmaceuticals announced a merger. These are the details.

MEI Pharma And Infinity Pharmaceuticals Announce Merger (MEIP) (INFI)

NEW YORK , Feb. 23, 2023 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) and its board of directors concerning the proposed acquisition of the company by MEI Pharma, Inc. (NASDAQ: MEIP). Infinity Pharmaceutical stockholders are expected to own 42% of the combined company.

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Infinity Pharmaceuticals, Inc.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of MEI Pharma, Inc. (NASDAQ: MEIP) and Infinity Pharmaceuticals, Inc. is fair to MEI shareholders. Per the merger agreement, pre-merger MEI shareholders are expected to own approximately 58.0% and pre-merger Infinity shareholders are expected to own approximately 42.0% of the outstanding equity of the combined company immediately following the merger.

MEIP STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Merger of MEI Pharma, Inc. Is Fair to Shareholders

SAN DIEGO, CA. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (“MEI”), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, and Infinity Pharmaceuticals, Inc.

MEI Pharma and Infinity Pharmaceuticals Announce Definitive Merger Agreement to Advance Three Promising Clinical Oncology Candidates

MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 150% and 237.82%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

MEI Pharma, Inc. (MEIP) Q2 Earnings and Revenues Top Estimates

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quarter ended December 31, 2022, and highlighted recent corporate events. “MEI anticipates reporting key clinical data readouts on two clinical-stage oncology candidates, voruciclib and ME-344, around the end of the calendar year for each program,” said Daniel P. Gold, Ph.D.

MEI Pharma Reports Second Quarter Fiscal Year 2023 Results and Operational Highlights

SAN DIEGO--( BUSINESS WIRE )--MEI Pharma, Inc. (Nasdaq: MEIP), a pharmaceutical company focused on advancing new therapies for cancer, announced today that its annual meeting of stockholders has been adjourned to January 5, 2023, at 9:00 a.m. Pacific Time. The record date for the adjourned annual meeting continues to be October 13, 2022.

MEI Pharma Announces Adjournment of Annual Meeting of Stockholders

SAN DIEGO--( BUSINESS WIRE )--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that it plans to initiate a realignment of its clinical development efforts following the discontinuation of global development outside Japan of its PI3K delta inhibitor, zandelisib. As part of the realignment, the company plans to streamline its organization towards the development of two earlier clinical-stage assets, voruciclib and ME-344. Following completion of the workforce reductions, MEI expects its existing cash, cash equivalents and marketable securities will be sufficient to fund operations through clinical data milestones for both voruciclib and ME-344. The company further announced that it has engaged Torreya Partners as financial advisor to help explore additional strategic opportunities.

MEI Pharma Initiates Strategic Realignment

SAN DIEGO & TOKYO--( BUSINESS WIRE )--MEI Pharma, Inc. (Nasdaq: MEIP), a pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a Japan-based global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced that after receiving the most recent guidance from a late November meeting with the U.S. Food and Drug Administration (FDA), the companies are discontinuing global development of zandelisib outside of Japan for B-cell malignancies. Kyowa Kirin is continuing the ongoing clinical trials including Phase 2 MIRAGE study evaluating Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphomas and will explore the potential for a submission to Japanese health authorities based on data from the MIRAGE and TIDAL clinical trials.

MEI Pharma and Kyowa Kirin Announce Discontinuation of Zandelisib Development Outside of Japan Following Recent FDA Meeting

TOKYO & SAN DIEGO--( BUSINESS WIRE )--Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology and MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced topline data from the Phase 2 MIRAGE study evaluating zandelisib, an orally administered investigational phosphatidylinositol 3-kinase delta ("PI3Kδ") inhibitor, in patients with indolent B-cell Non-Hodgkin's Lymphoma (iB-NHL) without small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL), and Waldenström's macroglobulinemia (WM) in Japan.

Kyowa Kirin and MEI Pharma Announce Topline Data from the Phase 2 MIRAGE Study Evaluating Zandelisib in Patients with Indolent B-cell non-Hodgkin's Lymphoma in Japan

MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 0% and 10.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

MEI Pharma, Inc. (MEIP) Reports Q1 Loss, Lags Revenue Estimates

SAN DIEGO--( BUSINESS WIRE )--MEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quarter ended September 30, 2022, and highlighted recent corporate events.

MEI Pharma Reports First Quarter Fiscal Year 2023 Results and Operational Highlights

SAN DIEGO & TOKYO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd.

MEI Pharma and Kyowa Kirin Announce Acceptance of Three Abstracts for Presentation at the American Society of Hematology Annual Meeting 2022

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the grant of inducement stock options for an aggregate of 131,000 shares of the company's common stock to four new employees. The stock options were granted as a material inducement to the new employees accepting employment with MEI in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have a $0.39 exercise price per share

MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that Christine A. White, M.D., has decided to retire and thus does not intend to stand for reelection at the Company's fiscal year 2023 annual meeting of stockholders after a seven-year tenure as chair of the board and 12 years total serving as a director. Charles V. Baltic III, J.D., who has served on the board since 2011, has been elec

MEI Pharma Announces Changes to Board of Directors

MEI Pharma, Inc. (NASDAQ:MEIP ) Q4 2022 Results Conference Call September 8, 2022 5:00 PM ET Company Participants David Walsey - Senior Vice President and Corporate Affairs Dan Gold - President and Chief Executive Officer Brian Drazba - Chief Financial Officer David Urso - Chief Operating Officer and General Counsel Richard Ghalie - Chief Medical Officer Conference Call Participants Stephen Willey - Stifel Robyn Karnauskas - Truist Yale Jen - Laidlaw & Co Nick Abbott - Wells Fargo Operator Good afternoon, and welcome to the MEI Pharma 2022 Fiscal Year End Conference Call. Please be advised that the call is being recorded at the Company's request.

MEI Pharma, Inc. (MEIP) Q4 2022 Earnings Call Transcript

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for its fiscal year ended June 30, 2022. "This past fiscal year was marked by progress on multiple fronts, including the first patient dosed in our Phase 3 COASTAL study, strong zandelisib data reported from the global Phase 2 TIDAL study, reporting of data from our voruciclib and ME-344 programs, and key appointments to our execu

MEI Pharma Reports Fiscal Year 2022 Results and Operational Highlights

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference 2022. The company will present a company overview and business update available for on-demand listening starting Monday, September 12, 2022, 7:00 a.m. Eastern Time that will be archived for 90 days. The presentation can be accessed via the Events & Pres

MEI Pharma to Present at the H.C. Wainwright 24th Annual Global Investment Conference 2022

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that the Company will release its 2022 fiscal year end financial results after the close of the U.S. financial markets on September 8, 2022. The Company will host a conference call and live webcast with the investment community to provide a corporate overview and update the same day at 5:00 p.m. ET. Conference Call & Webcast Informat

MEI Pharma to Release 2022 Fiscal Year End Financial Results and Provide Corporate Update on September 8, 2022

SAN DIEGO & TOKYO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced publication of data from the Phase 1b clinical study of zandelisib, an orally administered investigational phosphatidylinositol 3-kinase delta ("PI3Kδ") inhibitor,

MEI Pharma and Kyowa Kirin Announce Publication in The Lancet Oncology of Data from Phase 1b Clinical Study of Zandelisib in Patients with Relapsed or Refractory B-cell Malignancy

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that Anne Frese, an experienced industry executive, joined MEI as chief people officer, a role reporting to Daniel P. Gold, chief executive officer. Ms. Frese will be responsible for the strategy and processes related to building and retaining an exceptional team of professionals. Ms. Frese's appointment is effective immediately. Ms. Fre

MEI Pharma Appoints Human Resources Executive Anne Frese as Chief People Officer

Vinco Ventures

Mereo Biopharma Group Plc - ADR

Can these penny stocks continue to make gains The post Best Penny Stocks to Buy Right Now? 3 For Your Mid-June List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Buy Right Now? 3 For Your Mid-June List

SAN DIEGO & TOKYO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced that data from the zandelisib clinical development program, including the Phase 2 TIDAL study evaluating the intermittent dosing of zandelisib, an orally administe

MEI Pharma and Kyowa Kirin Report Clinical Data on Zandelisib at European Hematology Association 2022 Hybrid Congress

Brickell Biotech Inc

Cardiff Oncology

Sesen Bio Inc.

Biotech penny stocks to watch in June. The post Top Penny Stocks To Buy?

Top Penny Stocks To Buy? 4 Biotech Stocks To Watch Now

SAN DIEGO & TOKYO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced data from the ongoing Phase 2 TIDAL study evaluating the intermittent dosing of zandelisib, an orally administered investigational phosphatidylinositol 3-kinase de

News for MEI Pharma Stock (MEIP)